Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.04
FPMI's Cash to Debt is ranked lower than
54% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. FPMI: 0.04 )
FPMI' s 10-Year Cash to Debt Range
Min: 0.04   Max: No Debt
Current: 0.04

F-Score: 3
Z-Score: -107.29
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -3482.61
FPMI's ROE (%) is ranked lower than
53% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. FPMI: -3482.61 )
FPMI' s 10-Year ROE (%) Range
Min: -3482.61   Max: -176.8
Current: -3482.61

-3482.61
-176.8
ROA (%) -422.67
FPMI's ROA (%) is ranked lower than
52% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. FPMI: -422.67 )
FPMI' s 10-Year ROA (%) Range
Min: -866.67   Max: -100
Current: -422.67

-866.67
-100
ROC (Joel Greenblatt) (%) -9224.38
FPMI's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. FPMI: -9224.38 )
FPMI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4115.09   Max: -600
Current: -9224.38

-4115.09
-600
EPS Growth (%) 55.40
FPMI's EPS Growth (%) is ranked higher than
97% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. FPMI: 55.40 )
FPMI' s 10-Year EPS Growth (%) Range
Min: 0   Max: 100
Current: 55.4

0
100
» FPMI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with FPMI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
EV-to-EBIT -2.72
FPMI's EV-to-EBIT is ranked higher than
58% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. FPMI: -2.72 )
FPMI' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -2.72

Current Ratio 0.04
FPMI's Current Ratio is ranked lower than
54% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. FPMI: 0.04 )
FPMI' s 10-Year Current Ratio Range
Min: 0.04   Max: 21.99
Current: 0.04

0.04
21.99
Quick Ratio 0.04
FPMI's Quick Ratio is ranked lower than
54% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. FPMI: 0.04 )
FPMI' s 10-Year Quick Ratio Range
Min: 0.02   Max: 21.99
Current: 0.04

0.02
21.99

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) -37.60
FPMI's Earnings Yield (Greenblatt) is ranked higher than
53% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. FPMI: -37.60 )
FPMI' s 10-Year Earnings Yield (Greenblatt) Range
Min: -41.6   Max: 0
Current: -37.6

-41.6
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
FluoroPharma Medical Inc., is a molecular imaging company. It is engaged in the discovery, development and commercialization of proprietary products for the positron emission tomography (PET) market.
» More Articles for FPMI

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
FLUOROPHARMA MEDICAL, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Dec 12 2014
FluoroPharma Medical Announces Scheduled Completion of Enrollment in a Phase II Clinical Trial of... Dec 04 2014
FLUOROPHARMA MEDICAL, INC. Financials Nov 27 2014
10-Q for FluoroPharma Medical, Inc. Nov 21 2014
FPMI: CardioPET Data A Catalyst to Share Price Appreciation Nov 20 2014
FLUOROPHARMA MEDICAL, INC. Files SEC form 10-Q, Quarterly Report Nov 19 2014
Journal of Nuclear Cardiology Publication States Preliminary Findings of Phase II Clinical Study... Nov 03 2014
FPMI: Data Continues To Support Utility of CardioPET Oct 20 2014
FluoroPharma Announces That Data From Its Phase II Clinical Trial of 18-F FCPHA (CardioPET) Was... Oct 20 2014
FluoroPharma Medical Announces Acceptance of Abstract from Phase II Clinical Trial of CardioPET (18F... Oct 06 2014
FluoroPharma Announces That Data From Its Phase II Clinical Trial of 18-F FCPHA (CardioPET) Was... Sep 22 2014
FluoroPharma Medical Announces Acceptance of Abstract From Phase II Clinical Trial of CardioPET (18F... Sep 02 2014
FPMI: Positive CardioPET Data. Q2 Results Aug 20 2014
FLUOROPHARMA MEDICAL, INC. Files SEC form 10-Q, Quarterly Report Aug 14 2014
FLUOROPHARMA MEDICAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation... Jul 25 2014
FLUOROPHARMA MEDICAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Jul 01 2014
Eagle Pharmaceuticals (EGRX) in Focus: Stock Moves 5.6% Higher Jul 01 2014
FPMI: Additional Phase II Data Supports Utility of CardioPET Jun 11 2014
FluoroPharma Announces That Data From Its Phase II Clinical Trial of 18-F FCPHA (CardioPET) Was... Jun 11 2014
FluoroPharma Medical Announces Presentation of Data From Phase II Clinical Trial of 18F FCPHA... May 29 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK